![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 1042-1047, March 2003
New Product Research Laboratories II, Daiichi Pharmaceutical Co.,
Ltd., Tokyo, Japan
An alteration of the blood-brain barrier (BBB) permeability contributes
to the development of brain edema after stroke. In this study, we
evaluated the effects of
3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, on brain edema formation and BBB integrity in rats subjected to transient focal ischemia. DY-9760e (1 mg/kg/h) was intravenously infused for 6 h, starting immediately after reperfusion of a 1-h middle cerebral artery occlusion. Treatment with DY-9760e significantly suppressed the increase in water content and the extravasation of Evans
blue dye after transient focal ischemia. Analysis of a magnetic
resonance imaging method revealed that DY-9760e significantly prevented
the development of brain edema in the cortical region of the
ipsilateral hemisphere. Trifluoperazine, a calmodulin antagonist that
is structurally different from DY-9760e, also attenuated brain edema
elicited by transient focal ischemia. Furthermore, DY-9760e and
trifluoperazine reduced tumor necrosis factor-
-induced hyperpermeability of inulin through a cultured brain microvascular endothelial cell monolayer, suggesting an involvement of calmodulin in
the regulation of brain microvascular barrier function. The present
results demonstrate that DY-9760e ameliorates brain edema formation and
suggest that this effect may be mediated in part by the inhibition of
enhanced BBB permeability after ischemic insults. Thus, DY-9760e is
expected to be a therapeutic drug for treatment of acute stroke patients.
This article has been cited by other articles:
![]() |
S. Tachibana, Y. Fujimaki, H. Yokoyama, O. Okazaki, and K.-i. Sudo IN VITRO METABOLISM OF THE CALMODULIN ANTAGONIST DY-9760e (3-[2-[4-(3-CHLORO-2-METHYLPHENYL)-1-PIPERAZINYL]ETHYL]-5,6-DIMETHOXY-1-(4-IMIDAZOLYLMETHYL)-1H-INDAZOLE DIHYDROCHLORIDE 3.5 HYDRATE) BY HUMAN LIVER MICROSOMES: INVOLVEMENT OF CYTOCHROMES P450 IN ATYPICAL KINETICS AND POTENTIAL DRUG INTERACTIONS Drug Metab. Dispos., November 1, 2005; 33(11): 1628 - 1636. [Abstract] [Full Text] [PDF] |
||||